MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Watch Listen Read
Login Nexus Watchlists Settings
  • MARKETSnap
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Investment Compounding Calculator
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
Theme Style
Switch to Dark Mode
AXNX company logo - Stock analysis and financial data

AXNX

Axonics, Inc.

$70.98
 (%)
Exchange:   NASDAQ
Market Cap:   3.628B
Shares Outstanding:   18.378M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Raymond W. Cohen
Full Time Employees:  797
Address: 
26 Technology Drive
Irvine
CA
92618
US
Website:  https://www.axonics.com
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company’s SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

EPS

🔒 You are currently logged out

Login
View full analyst estimates

Earnings Call

🔒 You are currently logged out

Login
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Balance Sheet

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Cash Flow Statement

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Analyst Estimates

(* All numbers are in thousands)

🔒 You are currently logged out

Login

Current Key Metrics

🔒 You are currently logged out

Login

Forward P/E Ratios

🔒 You are currently logged out

Login

SWOT Analysis

🔒 You are currently logged out

Login

At what price to buy it? –
Intrinsic Value Calculator

🔒 Premium Feature

Log in to access the AXNX Intrinsic Value Calculator

🔑 Log In
📝 Sign Up Free

Get comprehensive stock analysis with premium features

🔒 You are currently logged out

Login
MS_Stock_Embed class not found. Please check plugin configuration.

Relevant news